The Multimodal MOPr/DOPr Agonist LP2 Reduces Allodynia in Chronic Constriction Injured Rats by Rescue of TGF-β1 Signalling

MLA

Annamaria Fidilio, et al. “The Multimodal MOPr/DOPr Agonist LP2 Reduces Allodynia in Chronic Constriction Injured Rats by Rescue of TGF-Β1 Signalling.” Frontiers in Pharmacology, vol. 12, Oct. 2021. EBSCOhost, https://doi.org/10.3389/fphar.2021.749365.

APA

Annamaria Fidilio, Margherita Grasso, Rita Turnaturi, Giuseppe Caruso, Federica Maria Spitale, Nunzio Vicario, Rosalba Parenti, Salvatore Spoto, Nicolò Musso, Agostino Marrazzo, Santina Chiechio, Filippo Caraci, Lorella Pasquinucci, & Carmela Parenti. (2021). The Multimodal MOPr/DOPr Agonist LP2 Reduces Allodynia in Chronic Constriction Injured Rats by Rescue of TGF-β1 Signalling. Frontiers in Pharmacology, 12. https://doi.org/10.3389/fphar.2021.749365

Chicago

Annamaria Fidilio, Margherita Grasso, Rita Turnaturi, Giuseppe Caruso, Federica Maria Spitale, Nunzio Vicario, Rosalba Parenti, et al. 2021. “The Multimodal MOPr/DOPr Agonist LP2 Reduces Allodynia in Chronic Constriction Injured Rats by Rescue of TGF-Β1 Signalling.” Frontiers in Pharmacology 12 (October). doi:10.3389/fphar.2021.749365.